Biomarkers in Nonalcoholic Fatty Liver Disease | Zendy

Manuela G. Neuman | Zendy; Lawrence B. Cohen | Zendy; Radu M. Nanau | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Biomarkers in Nonalcoholic Fatty Liver Disease

Author(s) -

Manuela G. Neuman,

Lawrence B. Cohen,

Radu M. Nanau

Publication year - 2014

Publication title -

canadian journal of gastroenterology and hepatology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.921

H-Index - 65

eISSN - 2291-2797

pISSN - 2291-2789

DOI - 10.1155/2014/757929

Subject(s) - medicine , adiponectin , fatty liver , nonalcoholic fatty liver disease , insulin resistance , biomarker , steatohepatitis , disease , gastroenterology , cirrhosis , leptin , metabolic syndrome , bioinformatics , insulin , obesity , biology , biochemistry

Nonalcoholic fatty liver disease (NAFLD) is a chronic liver condition characterized by insulin resistance, type 2 diabetes and fat accumulation in the liver that may cause hepatic inflammation and progressive scarring leading to nonalcoholic steatohepatitis (NASH) and irreversible liver damage (cirrhosis). As a result, there has been increased recognition of the need to assess and closely monitor individuals for risk factors of components of NAFLD and NASH, as well as the severity of these conditions using biomarkers.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research